Study of AK120 for teens with moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called AK120 for teenagers with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug can reduce itching and improve skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old and weigh at least 30 kg (about 66 pounds).
- You have had eczema for at least 6 months.
- Your eczema covers at least 10% of your body and is moderate to severe.
- You have had significant itching in the past week.
- You have not had certain eye conditions like vernal keratoconjunctivitis or atopic keratoconjunctivitis.
- You have not used certain traditional Chinese medicines or other study drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
This study tests a new medicine called AK120 in teenagers with moderate-to-severe atopic dermatitis (also known as eczema) that hasn't improved with other treatments. The goal is to see if AK120 can reduce itching and clear skin symptoms.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.